Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile

SIMPLE SUMMARY: Asunercept showed promising clinical efficacy in anemic, transfusion-dependent patients with low and intermediate risk myelodysplastic syndrome. In this retrospective post hoc analysis, serum levels of biomarkers were measured in study patients focusing on cytokines associated with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Radujkovic, Aleksandar, Boch, Tobias, Nolte, Florian, Nowak, Daniel, Kunz, Claudia, Gieffers, Alexandra, Müller-Tidow, Carsten, Dreger, Peter, Hofmann, Wolf-Karsten, Luft, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764464/
https://www.ncbi.nlm.nih.gov/pubmed/33302451
http://dx.doi.org/10.3390/cancers12123683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764464/
https://www.ncbi.nlm.nih.gov/pubmed/33302451
http://dx.doi.org/10.3390/cancers12123683

Ejemplares similares